文献速递细胞病理与分子病理

影像引导FNA的快速现场评估提高临床试验患者后续粗针活检充分性:分析前因素影响及其与生存的相关性

Rapid on-site evaluation (ROSE) of image-guided FNA specimens improves subsequent core biopsy adequacy in clinical trial patients: The impact of preanalytical factors and its correlation with survival.
PubMed 文献 · Cancer Cytopathol · 2023-09-28

BMI 25.0-34.9 kg/m2患者生存优于体重不足或III度肥胖者(p<.01)。

要点

  • 超声引导FNA样本充分率显著高于CT引导(83% vs 59%,p<.01)
  • BMI 25.0-34.9 kg/m2患者总生存优于BMI<18.5或>35.0 kg/m2者(p<.01)

核心结论

  • 推荐超声引导获取临床试验FNA样本以提高充分性。
  • BMI轻度升高(25.0-34.0 kg/m2)的癌症患者在本队列中总生存增加。

研究设计与样本

  • 所有患者均行ROSE,由细胞技术员评估样本充分性;使用SPSS 28进行统计分析。

主要发现

  • 影像引导方式主要为超声引导(n=267;82%)和CT引导(n=58;18%)。
  • 超声引导活检充分率83%显著高于CT引导59%(p<.01)。
  • BMI 25.0-34.9 kg/m2患者生存优于BMI<18.5 kg/m2或>35.0 kg/m2者(p<.01)。

关键数值与推荐

  • 超声引导vs CT引导充分率:83% vs 59%(p<.01)。
  • 生存分析BMI分组:25.0-34.9 kg/m2 vs <18.5 kg/m2或>35.0 kg/m2(p<.01)。

临床怎么用

  • 临床试验中优先采用超声引导FNA并结合ROSE以确保样本充分。
  • 关注患者BMI对生存的潜在影响,但需进一步验证。

局限性

  • 回顾性单中心设计,样本来自特定临床试验人群。
  • ROSE评估由细胞技术员完成,未提及病理医师复核。
  • BMI与生存的关联为观察性发现,不能推断因果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sufficient tumor collection has become of utmost importance in therapeutic experimental protocols. Rapid on-site evaluation (ROSE) ensures adequate sampling for quantification of biomarkers, molecular analyses, and other ancillary studies. The objectives of this study were to evaluate the role of ROSE in trial-associated fine-needle aspiration (FNA) and to analyze predictors of adequacy and cumulative survival from in-house FNA cases used in clinical trials. METHODS: Clinical trial FNA biopsies performed at a large academic institution were analyzed over 10 months using a comprehensive chart review of the electronic medical records. SPSS version 28 was used for statistical analysis. RESULTS: Three hundred twenty-five FNAs were collected for 57 clinical trials. In total, 225 individual patients had an average of 1.4 FNA procedures each as a result of a multidepartmental collaborative effort. ROSE was performed for all patients, and adequacy was evaluated by cytotechnologists. Seventy-eight percent of samples were considered adequate, 14% were considered less than optimal, and 8% were considered inadequate, with the latter two categories designated together as less than adequate. The imaging modalities were mainly ultrasound-guided (n = 267; 82%) and computed tomography-guided (n = 58; 18%). There was a statistically significant association between adequate sampling and ultrasound-guided biopsies (83%) compared with computed tomography-guided biopsies (59%; p < .01). The effect of body mass index (BMI) on mortality was also a significant finding. The authors observed a survival benefit in patients who had elevated BMIs (range, 25.0-34.9 kg/m2 ) compared with those who were underweight (BMI, <18.5 kg/m2 ) or class III obese (BMI, >35.0 kg/m2 ; p < .01). Therefore, the best predictors of adequacy and mortality were imaging modality and BMI, respectively. CONCLUSIONS: Ultrasound-guided modalities are recommended for obtaining adequate FNA sampling for clinical trials. In addition, patients with cancer who had slightly elevated BMIs (25.0-34.0 kg/m2 ) had increased overall survival in this cohort.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Graham AJ, Robinson MT, Kahler J, et al. Rapid on-site evaluation (ROSE) of image-guided FNA specimens improves subsequent core biopsy adequacy in clinical trial patients: The impact of preanalytical factors and its correlation with survival. Cancer Cytopathol. 2023. PMID: 37768842. doi:10.1002/cncy.22764

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。